AstraZeneca logo

AZN - AstraZeneca Share Price

8796.5p 148.5  1.7%

Last Trade - 11:26am

Sector
Healthcare
Size
Large Cap
Market Cap £113.49bn
Enterprise Value £125.09bn
Revenue £19.81bn
Position in Universe 6th / 1807
Bullish
Bearish
Unlock AZN Revenue
Momentum
Relative Strength (%)
1m +2.05%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -14.5%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
26,547 24,708 23,002 22,465 22,090 24,384 26,608 29,770 -1.7%
+102.7 +0.5 -39.2 -45.7 -37.6 +73.9 +165.9 +25.1
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2020, AstraZeneca plc revenues increased 12% to $12.63B. Net income increased from $723M to $1.54B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from Finance expense decrease of 9% to $661M (expense), SGA Restructuring Charges/Provisions decrease of 59% to $45M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for AZN
Graphical History

Revenue

AZN Revenue Unlock AZN Revenue

Net Income

AZN Net Income Unlock AZN Revenue

Normalised EPS

AZN Normalised EPS Unlock AZN Revenue

PE Ratio Range

AZN PE Ratio Range Unlock AZN Revenue

Dividend Yield Range

AZN Dividend Yield Range Unlock AZN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
AZN EPS Forecasts Unlock AZN Revenue
Profile Summary

AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.

Directors
Last Annual December 31st, 2019
Last Interim June 30th, 2020
Incorporated June 17, 1992
Public Since September 21, 2007
No. of Shareholders: 77,752
No. of Employees: 70,600
AZN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for AZN
Upcoming Events for AZN
Frequently Asked Questions for AstraZeneca
What is the AstraZeneca share price?

As of 11:26am, shares in AstraZeneca are trading at 8796.5p, giving the company a market capitalisation of £113.49bn. This share price information is delayed by 15 minutes.

How has the AstraZeneca share price performed this year?

Shares in AstraZeneca are currently trading at 8796.5p and the price has moved by 24.49% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the AstraZeneca price has moved by 48.32% over the past year.

What are the analyst and broker recommendations for AstraZeneca?

Of the analysts with advisory recommendations for AstraZeneca, there are there are currently 8 "buy" , 3 "hold" and 1 "sell" recommendations. The overall consensus recommendation for AstraZeneca is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will AstraZeneca next release its financial results?

AstraZeneca is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the AstraZeneca dividend yield?

The AstraZeneca dividend yield is 2.5% based on the trailing twelve month period.

Does AstraZeneca pay a dividend?

Last year, AstraZeneca paid a total dividend of 2.8, and it currently has a trailing dividend yield of 2.5%. Looking ahead, AstraZeneca has not announced an ex-dividend date yet.

When does AstraZeneca next pay dividends?

AstraZeneca has yet to annouce their ex-dividend date. The historic dividend yield on AstraZeneca shares is currently 2.5%.

How do I buy AstraZeneca shares?

To buy shares in AstraZeneca you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of AstraZeneca?

Shares in AstraZeneca are currently trading at 8796.5p, giving the company a market capitalisation of £113.49bn.

Where are AstraZeneca shares listed? Where are AstraZeneca shares listed?

Here are the trading details for AstraZeneca:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: AZN
What kind of share is AstraZeneca?

Based on an overall assessment of its quality, value and momentum, AstraZeneca is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a AstraZeneca share price forecast 2020?

Shares in AstraZeneca are currently priced at 8796.5p. At that level they are trading at 0.88% premium to the analyst consensus target price of 8,719.77.

Analysts covering AstraZeneca currently have a consensus Earnings Per Share (EPS) forecast of 3.948 for the next financial year.

How can I tell whether the AstraZeneca share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AstraZeneca. Over the past six months, the relative strength of its shares against the market has been 0.84%. At the current price of 8796.5p, shares in AstraZeneca are trading at 8.33% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the AstraZeneca PE Ratio?

The AstraZeneca PE ratio based on its reported earnings over the past 12 months is 73.77. The shares are currently trading at 8796.5p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of AstraZeneca?

AstraZeneca's management team is headed by:

Marcus Wallenberg - NED
Katarina Ageborg - EVP
Pascal Soriot - CEO
Leif Johansson - NEC
Graham Chipchase - NID
Genevieve Berger - NID
Marc Dunoyer - CFO
Ruud Dobber - EVP
Menelas Pangalos - EVP
Fiona Cicconi - EVP
Pam Cheng - EVP
Philip Broadley - NID
David Fredrickson - EVP
Iskra Reic - EVP
Jose Baselga - EVP
Who are the major shareholders of AstraZeneca?

Here are the top five shareholders of AstraZeneca based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 7.69% (100.9m shares)
Capital Research Global Investors Investment Advisor
Percentage owned: 4.86% (63.8m shares)
Investor AB Private Equity
Percentage owned: 3.93% (51.6m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 3.41% (44.8m shares)
Wellington Management Company, LLP Investment Advisor/Hedge Fund
Percentage owned: 2.95% (38.7m shares)
Similar to AZN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.